SAN FRANCISCO, Aug. 30, 2017 -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, announced today that healthcare industry leader Daniel Wolterman has been appointed to its Board of Directors, effective September 5, 2017. Wolterman was most recently President & Chief Executive Officer of Memorial Herman Healthcare System.
"We are pleased to welcome Dan to Invuity’s Board of Directors," said Invuity Chief Executive Officer Philip Sawyer. "His significant insight into healthcare systems will be extremely valuable as we continue to grow our business by providing innovative product solutions to our hospital customers."
Wolterman joined Memorial Hermann Healthcare System in May 1999. He was named Chief Executive Officer in November 2002 and retired in August 2016. Under Wolterman’s leadership, Memorial Hermann became one of the largest healthcare systems in Texas, operating in 16 hospitals and over 232 ancillary locations with 24,000 employees and is now the country’s busiest Level 1 trauma center and generating $6.0 billion in net revenue. Prior to Memorial Hermann, Wolterman was Senior Vice President, Operations & Business Development at Sisters of Charity of the Incarnate Word Health Care System from 1993 to 1999 and President & CEO of Holy Cross Health Services of Utah from 1989 to 1993. Wolterman currently serves on the Boards of Directors of Nuvasive (Nasdaq:NUVA), Vizient, Inc. and Legacy ER & Urgent Care.
"I'm excited about the opportunity to work with the management team and board to assist Invuity in realizing its significant potential," said Wolterman. "The company’s proprietary technologies and innovative product solutions provide a meaningful clinical benefit to physicians, patients and health care systems.”
About Invuity®
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's patented Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
CONTACT: Company Contact: Jim Mackaness Chief Financial Officer Invuity, Inc. 415-655-2129 Investors: Mark Klausner Westwicke Partners 443-213-0501 [email protected]


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Italy Fines Apple €98.6 Million Over App Store Dominance
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 



